SexNCT05279053
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
An observational study of Sex and Cigarette Smoking, run by University of California, Los Angeles at 1 site in United States.
Trial summary
The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Sex, Cigarette Smoking
- What is being tested?
- Abstinence and Smoking
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 58 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2021to 31 Mar 2023
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Target recruitment: 60 adult daily smokers (30 men and 30 women; 18-45 years old), who are otherwise in good health. Interested individuals will be invited to participate in the research project regardless of sex, race or ethnicity, although strong efforts will be made to recruit equal numbers of male and female participants. Individuals will not be excluded from study participation based on race/ethnicity.
Who may be able to join
- Self-identified as only male or female
- Age 18-45 years (children <18 years will be excluded due to low prevalence of conventional cigarette smoking; female participants >45 years of age will be excluded to avoid effects of perimenopause and menopause in women; male participants >45 years of age will be excluded as well to ensure that male and female groups are matched on age
- English fluency demonstrated by verbal skills sufficient to participate in a conversation, including the ability to ask and answer questions at a level that assures adequate understanding of the study (a comprehension quiz will be given)
- Right handedness (evaluated using the Edinburgh Inventory)
- Generally in good health without cardiovascular, hepatic, renal, or autoimmune diseases, diabetes, or cancer
- Must have smoked for ≥1 year
Show all 10Show fewer
- Must endorse inhaling while smoking
- Must smoke ≥10 cigarettes per day
- Must have expired CO >10 ppm and urinary cotinine ≥100 ng/ml at screening/intake
- Fulfillment of DSM-5 criteria for Tobacco Use Disorder
Who cannot join
- Seeking treatment for nicotine dependence within 3 months of screening
- Medical condition that may compromise safety (based on history, physical exam)
- Neurological disorder that would compromise compliance and/or informed consent
- Major psychiatric disorder (e.g., Major Depression, Schizophrenia, Bipolar Disorder) per DSM-5 MINI
- Current drug use disorders other than Tobacco Use Disorder (as defined in DSM-5)
- Recent use of cocaine, opiates, benzodiazepines, or amphetamines as shown by urine test at the screening or testing sessions
Show all 13Show fewer
- Smoke marijuana >3X/week (self-report) or positive marijuana urine test on a scan day (positive at screening allowed)
- Use of tobacco in forms other than cigarettes (e.g., snuff, chewing tobacco, e-cigarettes) >10 days in the month before screening
- Preference for menthol cigarettes, given sex differences in the effect of menthol on the rate of nicotine entry into the brain
- Pregnancy or nursing
- Presence in the body of metal that would compromise safety during MRI
- Claustrophobia
- Any other condition that would compromise safety
Trial locations and contacts
1 site in 1 country.
About this study
The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu was measured in the entire brain with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) were measured for female participants to determine relationships between brain Glu and this hormone. Glu was be measured in smokers after overnight (~12 h) abstinence and after participants smoked the first cigarette of the day.
Read the detailed description
Glutamatergic signaling is dysregulated in addictions, including Tobacco Use Disorder (TUD) , and represents a promising target for smoking cessation therapies. In rodents, NMDA-type glutamate (Glu) receptor antagonists reduce nicotine-seeking behavior, whereas pre-treatment with NMDA-type and AMPA-type Glu receptor antagonists attenuates nicotine self-administration and nicotine-induced dopamine release. In humans, N-acetylcysteine, which regulates Glu via the cysteine-glutamate antiporter and glial Glu transporter, reduces cigarette smoking9 as well as cortical and subcortical levels of Glu itself, measured by magnetic resonance spectroscopy (MRS). These observations suggest that Glu, assayed by MRS, which is a safe and non-invasive in vivo metric, may aid in tracking regional effects of smoking and of anti-smoking interventions.
Notably, evidence has been provided that Glu in the dorsal anterior cingulate cortex (dACC) is associated with smoking-related states, that Glx (the sum of Glu and its primary metabolite, glutamine, Gln) in dACC is higher in smokers than nonsmokers, and that Glx in the insula is higher after overnight abstinence from smoking than during satiety. Further, studies in smokers combining functional magnetic resonance imaging (fMRI) with MRS have linked dACC Glu with activation of the Default Mode Network during cue-induced cigarette craving, and demonstrated reduced dACC Glx and altered dACC-to-DMN connectivity following varenicline treatment. Prior MRS studies of smoking, however, have been limited by single-voxel techniques that sample single brain regions with restricted spatial-resolution and partial volume effects (i.e., including more than one tissue type in the acquisition voxel).
We will exploit the echo-planar spectroscopic imaging (EPSI) variant of MRS in a high-density, anatomically broad assessment of how sex, acute smoking, and ovarian hormones affect brain Glu. Our pilot data indicate that dACC Glu is lower in smoking-abstinent women than men, and lower still in women with higher serum estrogen. After smoking, dACC Glu decreases in men but not in women.
We will use EPSI to determine whether our dACC Glu pilot findings: 1) replicate at high spatial resolution; 2) pertain to the anterior insula and thalamus, which are also implicated in TUD, and 3) on an exploratory basis, pertain to other regions in the rest of the brain. To accomplish this, we will use a recently developed short echo-time (TE=20 ms) variant of 3D EPSI at 3-Tesla. With this state-of-the-art technique, we typically acquire high-quality spectra simultaneously from ~80% of the brain at the very high spatial resolution of ~0.4 cc. Short-TE, moreover, improves segregation of Glu from the overlapping Gln signal.
We teste adult daily smokers (men and women) before and after their first cigarette of the day after ~12 h abstinence. Serum estrogen and progesterone in women were assayed. We addressed two specific aims:
Aim 1: Determine relationships between brain Glu, sex, and circulating ovarian hormones. Hypothesis 1a: Our single-voxel MRS finding that men have higher Glu in the dACC than women after overnight abstinence from smoking will be replicated with EPSI, and will extend to the anterior insula and thalamus. Hypothesis 1b: EPSI will replicate our preliminary finding that Glu in the dACC correlates negatively with serum estrogen (and possibly progesterone) in women, and will show similar relationships of ovarian hormones with the anterior insula and thalamus.
Aim 2: Determine sex differences in acute effects of smoking on brain Glu. Hypothesis 2: The preliminary finding that Glu decreases after acute smoking in the dACC of men but increases or is unchanged in women will be replicated, and will extend to other brain regions.
Ultimately, measurements of sex differences in Glu in specific brain regions, and how Glu changes with smoking and ovarian hormones, can define biomarkers that facilitate development of novel treatments and evaluate therapeutic response in men and women.
- Conditions
- Sex, Cigarette Smoking
- Being tested
- Abstinence and Smoking
- Medical subject headings
- Coitus, Cigarette Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Abstinence and SmokingBehavioural
Participants came to the lab after overnight abstinence from smoking and smoked their first cigarette of the day.
| Study group | Role | What they receive |
|---|---|---|
| Male adults who endorse daily smoking | Participants recruited for this study will be male adults (18-45 years old), who smoke cigarettes daily and are generally in good health. They will have no other drug use, other than occasional marijuana or alcohol use, and no major psychiatric disorders. Urine and breath tested metrics will be used to establish whether participants meet drug use-related criteria. Receives: Behavioral: Abstinence and Smoking | |
| Female adults who endorse daily smoking | Participants recruited for this study will be female adults (18-45 years old), who smoke cigarettes daily and are generally in good health. They will have no other drug use, other than occasional marijuana or alcohol use, and no major psychiatric disorders. Urine and breath tested metrics will be used to establish whether participants meet drug use-related criteria. Receives: Behavioral: Abstinence and Smoking |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glutamate in the Dorsal Anterior Cingulate Cortex
Glutamate levels, as measured using MRS, in the dorsal anterior cingulate cortex.
Measured: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Glutamate in the Insula
Glutamate levels, as measured using MRS, in the insula.
Measured: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Glutamate in Whole Brain (Gray Matter Plus White Matter).
Glutamate measured using the MRS echoplanar spectroscopic imaging in abstinent smokers.
Measured: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Serum Estrogen
Estrogen concentration measured in serum from blood samples drawn prior to MRS (women only).
Measured: Sampling performed on same day as MRS (before smoking).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2022
- Study start1 Apr 2021
- Primary completion31 Mar 2023
- Study completion31 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for SexStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 58 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Principal investigator, Edythe London, University of California, Los Angeles
- Investigators
- Edythe London, PhD, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05279053
- Sponsor's protocol ID
- UCLA IRB 17-000387
- Other IDs
- 5R03DA052719
- Status last verified
- Mar 2026
- First submitted
- 23 Feb 2022
- Last updated
- 20 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
- ClinicalTrials.gov ID
- NCT05279053
- Acronym / sponsor ID
- UCLA IRB 17-000387
- Conditions
- Sex, Cigarette Smoking
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 58 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 31 Mar 2023 (actual)
- Study completion
- 31 Mar 2023 (actual)
- First posted
- 15 Mar 2022 (actual)
- Results
- Posted 20 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu was measured in the entire brain with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) were measured for female participants to determine relationships between brain Glu and this hormone. Glu was be measured in smokers after overnight (~12 h) abstinence and after participants smoked the first cigarette of the day.
Detailed description
Glutamatergic signaling is dysregulated in addictions, including Tobacco Use Disorder (TUD) , and represents a promising target for smoking cessation therapies. In rodents, NMDA-type glutamate (Glu) receptor antagonists reduce nicotine-seeking behavior, whereas pre-treatment with NMDA-type and AMPA-type Glu receptor antagonists attenuates nicotine self-administration and nicotine-induced dopamine release. In humans, N-acetylcysteine, which regulates Glu via the cysteine-glutamate antiporter and glial Glu transporter, reduces cigarette smoking9 as well as cortical and subcortical levels of Glu itself, measured by magnetic resonance spectroscopy (MRS). These observations suggest that Glu, assayed by MRS, which is a safe and non-invasive in vivo metric, may aid in tracking regional effects of smoking and of anti-smoking interventions.
Notably, evidence has been provided that Glu in the dorsal anterior cingulate cortex (dACC) is associated with smoking-related states, that Glx (the sum of Glu and its primary metabolite, glutamine, Gln) in dACC is higher in smokers than nonsmokers, and that Glx in the insula is higher after overnight abstinence from smoking than during satiety. Further, studies in smokers combining functional magnetic resonance imaging (fMRI) with MRS have linked dACC Glu with activation of the Default Mode Network during cue-induced cigarette craving, and demonstrated reduced dACC Glx and altered dACC-to-DMN connectivity following varenicline treatment. Prior MRS studies of smoking, however, have been limited by single-voxel techniques that sample single brain regions with restricted spatial-resolution and partial volume effects (i.e., including more than one tissue type in the acquisition voxel).
We will exploit the echo-planar spectroscopic imaging (EPSI) variant of MRS in a high-density, anatomically broad assessment of how sex, acute smoking, and ovarian hormones affect brain Glu. Our pilot data indicate that dACC Glu is lower in smoking-abstinent women than men, and lower still in women with higher serum estrogen. After smoking, dACC Glu decreases in men but not in women.
We will use EPSI to determine whether our dACC Glu pilot findings: 1) replicate at high spatial resolution; 2) pertain to the anterior insula and thalamus, which are also implicated in TUD, and 3) on an exploratory basis, pertain to other regions in the rest of the brain. To accomplish this, we will use a recently developed short echo-time (TE=20 ms) variant of 3D EPSI at 3-Tesla. With this state-of-the-art technique, we typically acquire high-quality spectra simultaneously from ~80% of the brain at the very high spatial resolution of ~0.4 cc. Short-TE, moreover, improves segregation of Glu from the overlapping Gln signal.
We teste adult daily smokers (men and women) before and after their first cigarette of the day after ~12 h abstinence. Serum estrogen and progesterone in women were assayed. We addressed two specific aims:
Aim 1: Determine relationships between brain Glu, sex, and circulating ovarian hormones. Hypothesis 1a: Our single-voxel MRS finding that men have higher Glu in the dACC than women after overnight abstinence from smoking will be replicated with EPSI, and will extend to the anterior insula and thalamus. Hypothesis 1b: EPSI will replicate our preliminary finding that Glu in the dACC correlates negatively with serum estrogen (and possibly progesterone) in women, and will show similar relationships of ovarian hormones with the anterior insula and thalamus.
Aim 2: Determine sex differences in acute effects of smoking on brain Glu. Hypothesis 2: The preliminary finding that Glu decreases after acute smoking in the dACC of men but increases or is unchanged in women will be replicated, and will extend to other brain regions.
Ultimately, measurements of sex differences in Glu in specific brain regions, and how Glu changes with smoking and ovarian hormones, can define biomarkers that facilitate development of novel treatments and evaluate therapeutic response in men and women.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Male adults who endorse daily smoking | – | Behavioral: Abstinence and SmokingParticipants recruited for this study will be male adults (18-45 years old), who smoke cigarettes daily and are generally in good health. They will have no other drug use, other than occasional marijuana or alcohol use, and no major psychiatric disorders. Urine and breath tested metrics will be used to establish whether participants meet drug use-related criteria. |
| Female adults who endorse daily smoking | – | Behavioral: Abstinence and SmokingParticipants recruited for this study will be female adults (18-45 years old), who smoke cigarettes daily and are generally in good health. They will have no other drug use, other than occasional marijuana or alcohol use, and no major psychiatric disorders. Urine and breath tested metrics will be used to establish whether participants meet drug use-related criteria. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Target recruitment: 60 adult daily smokers (30 men and 30 women; 18-45 years old), who are otherwise in good health. Interested individuals will be invited to participate in the research project regardless of sex, race or ethnicity, although strong efforts will be made to recruit equal numbers of male and female participants. Individuals will not be excluded from study participation based on race/ethnicity.
Key inclusion criteria (10 listed)
- Self-identified as only male or female
- Age 18-45 years (children <18 years will be excluded due to low prevalence of conventional cigarette smoking; female participants >45 years of age will be excluded to avoid effects of perimenopause and menopause in women; male participants >45 years of age will be excluded as well to ensure that male and female groups are matched on age
- English fluency demonstrated by verbal skills sufficient to participate in a conversation, including the ability to ask and answer questions at a level that assures adequate understanding of the study (a comprehension quiz will be given)
- Right handedness (evaluated using the Edinburgh Inventory)
- Generally in good health without cardiovascular, hepatic, renal, or autoimmune diseases, diabetes, or cancer
Key exclusion criteria (13 listed)
- Seeking treatment for nicotine dependence within 3 months of screening
- Medical condition that may compromise safety (based on history, physical exam)
- Neurological disorder that would compromise compliance and/or informed consent
- Major psychiatric disorder (e.g., Major Depression, Schizophrenia, Bipolar Disorder) per DSM-5 MINI
- Current drug use disorders other than Tobacco Use Disorder (as defined in DSM-5)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Abstinence and SmokingParticipants came to the lab after overnight abstinence from smoking and smoked their first cigarette of the day. | Behavioural | Female adults who endorse daily smoking, Male adults who endorse daily smoking |
Primary outcome
Glutamate in the Dorsal Anterior Cingulate Cortex
Time frame: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Glutamate levels, as measured using MRS, in the dorsal anterior cingulate cortex.
Glutamate in the Insula
Time frame: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Glutamate levels, as measured using MRS, in the insula.
Glutamate in Whole Brain (Gray Matter Plus White Matter).
Time frame: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.
Glutamate measured using the MRS echoplanar spectroscopic imaging in abstinent smokers.
Serum Estrogen
Time frame: Sampling performed on same day as MRS (before smoking).
Estrogen concentration measured in serum from blood samples drawn prior to MRS (women only).
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Sex
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Recruiting
PRP for Sexual Function
Female Sexual Dysfunction, Sexual Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Edythe London, PhD principal investigator
University of California, Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sex and Cigarette Smoking, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glutamate in the Dorsal Anterior Cingulate Cortex (time frame: Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.